Published in Cancer Res on January 15, 2006
The emerging role of splicing factors in cancer. EMBO Rep (2008) 1.83
HMGB1 in health and disease. Mol Aspects Med (2014) 1.67
Comprehensive proteome analysis of an Apc mouse model uncovers proteins associated with intestinal tumorigenesis. Cancer Prev Res (Phila) (2009) 1.27
Subnuclear proteomics in colorectal cancer: identification of proteins enriched in the nuclear matrix fraction and regulation in adenoma to carcinoma progression. Mol Cell Proteomics (2010) 1.16
Identification of candidate biomarkers for early detection of human lung squamous cell cancer by quantitative proteomics. Mol Cell Proteomics (2012) 1.04
Control of creatine metabolism by HIF is an endogenous mechanism of barrier regulation in colitis. Proc Natl Acad Sci U S A (2013) 1.04
miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2. Cell Death Dis (2015) 1.00
Co-expression of nuclear and cytoplasmic HMGB1 is inversely associated with infiltration of CD45RO+ T cells and prognosis in patients with stage IIIB colon cancer. BMC Cancer (2010) 0.99
A glycine-rich domain of hnRNP H/F promotes nucleocytoplasmic shuttling and nuclear import through an interaction with transportin 1. Mol Cell Biol (2010) 0.98
An investigation into the cytotoxic effects of 13-acetoxysarcocrassolide from the soft coral Sarcophyton crassocaule on bladder cancer cells. Mar Drugs (2011) 0.97
Creatine kinase brain overexpression protects colorectal cells from various metabolic and non-metabolic stresses. J Cell Biochem (2011) 0.87
2D-difference gel electrophoretic proteomic analysis of a cell culture model of alveolar rhabdomyosarcoma. J Proteome Res (2011) 0.84
High-mobility group box 2 is associated with prognosis of glioblastoma by promoting cell viability, invasion, and chemotherapeutic resistance. Neuro Oncol (2013) 0.83
Regulation of T cell development and activation by creatine kinase B. PLoS One (2009) 0.83
A network-based analysis of colon cancer splicing changes reveals a tumorigenesis-favoring regulatory pathway emanating from ELK1. Genome Res (2016) 0.82
High-mobility group box 2 (HMGB2) modulates radioresponse and is downregulated by p53 in colorectal cancer cell. Cancer Biol Ther (2012) 0.81
A link between FXYD3 (Mat-8)-mediated Na,K-ATPase regulation and differentiation of Caco-2 intestinal epithelial cells. Mol Biol Cell (2008) 0.81
Chronic low-level Pb exposure during development decreases the expression of the voltage-dependent anion channel in auditory neurons of the brainstem. Neurotoxicology (2010) 0.80
Differential protein expression of Caco-2 cells treated with selenium nanoparticles compared with sodium selenite and selenomethionine. Nanoscale Res Lett (2014) 0.75
Creatine kinase in ischemic and inflammatory disorders. Clin Transl Med (2016) 0.75
Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities. J Natl Cancer Inst (2010) 3.16
Retracted EPCA-2: a highly specific serum marker for prostate cancer. Urology (2007) 2.67
Analysis of colorectal cancer occurrence during surveillance colonoscopy in the dietary Polyp Prevention Trial. Gastrointest Endosc (2005) 2.63
Identification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis. Gastroenterology (2012) 2.57
Ongoing colorectal cancer risk despite surveillance colonoscopy: the Polyp Prevention Trial Continued Follow-up Study. Gastrointest Endosc (2009) 2.55
Meta-analysis of new genome-wide association studies of colorectal cancer risk. Hum Genet (2011) 2.35
Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial. J Natl Cancer Inst (2005) 2.27
Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology (2005) 2.10
Applying a natural language processing tool to electronic health records to assess performance on colonoscopy quality measures. Gastrointest Endosc (2012) 1.96
Pooled analysis of genetic variation at chromosome 8q24 and colorectal neoplasia risk. Hum Mol Genet (2008) 1.96
Inhibition of histone deacetylase expands the renal progenitor cell population. J Am Soc Nephrol (2010) 1.94
Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med (2009) 1.94
Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages. Nat Chem Biol (2009) 1.88
Regulation of the autophagy protein LC3 by phosphorylation. J Cell Biol (2010) 1.86
Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites. Nat Chem Biol (2007) 1.83
A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach. J Med Chem (2005) 1.80
Early identification of individuals with prostate cancer in negative biopsies. J Urol (2004) 1.78
Informed decision-making and colorectal cancer screening: is it occurring in primary care? Med Care (2008) 1.75
The cancer/testis antigen prostate-associated gene 4 (PAGE4) is a highly intrinsically disordered protein. J Biol Chem (2011) 1.68
Nuclear matrix protein alterations associated with colon cancer metastasis to the liver. Clin Cancer Res (2002) 1.65
DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med (2013) 1.63
The yield of surveillance colonoscopy by adenoma history and time to examination. Clin Gastroenterol Hepatol (2008) 1.61
Utilization and yield of surveillance colonoscopy in the continued follow-up study of the polyp prevention trial. Clin Gastroenterol Hepatol (2008) 1.58
Characterization of gene-environment interactions for colorectal cancer susceptibility loci. Cancer Res (2012) 1.58
A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients. Cancer Prev Res (Phila) (2012) 1.57
APC is essential for targeting phosphorylated beta-catenin to the SCFbeta-TrCP ubiquitin ligase. Mol Cell (2008) 1.54
Guidelines for reporting the use of gel electrophoresis in proteomics. Nat Biotechnol (2008) 1.54
Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc Natl Acad Sci U S A (2002) 1.53
Retracted Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer. Clin Cancer Res (2008) 1.51
Small molecule modulators of endogenous and co-chaperone-stimulated Hsp70 ATPase activity. J Biol Chem (2004) 1.51
Supplementation with oral vs. intravenous iron for anemia with IBD or gastrointestinal bleeding: is oral iron getting a bad rap? Am J Gastroenterol (2011) 1.48
Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology (2005) 1.48
Tobacco smoking and colorectal hyperplastic and adenomatous polyps. Cancer Epidemiol Biomarkers Prev (2006) 1.46
Biomarkers for prostate cancer. Annu Rev Med (2009) 1.45
Relationship between detection of adenomas by flexible sigmoidoscopy and interval distal colorectal cancer. Clin Gastroenterol Hepatol (2012) 1.44
PUMA-mediated intestinal epithelial apoptosis contributes to ulcerative colitis in humans and mice. J Clin Invest (2011) 1.43
Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells. Mol Cancer Ther (2009) 1.42
Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev (2008) 1.42
Physicians encouraging colorectal screening: a randomized controlled trial of enhanced office and patient management on compliance with colorectal cancer screening. Arch Intern Med (2009) 1.41
MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila) (2012) 1.39
Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly. Mol Pharmacol (2006) 1.36
Developing a natural language processing application for measuring the quality of colonoscopy procedures. J Am Med Inform Assoc (2011) 1.28
Variation in the selenoenzyme genes and risk of advanced distal colorectal adenoma. Cancer Epidemiol Biomarkers Prev (2008) 1.27
Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination. J Natl Cancer Inst (2012) 1.27
Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis. Proc Natl Acad Sci U S A (2010) 1.26
Hyperthermic biology and cancer therapies: a hypothesis for the "Lance Armstrong effect". JAMA (2006) 1.26
Expression of cancer/testis antigens in prostate cancer is associated with disease progression. Prostate (2010) 1.21
Circulating vitamin D metabolites, polymorphism in vitamin D receptor, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev (2004) 1.20
Cancer/Testis Antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. J Transl Med (2011) 1.19
Histone deacetylase inhibitor enhances recovery after AKI. J Am Soc Nephrol (2013) 1.19
Chemical library screens targeting an HIV-1 accessory factor/host cell kinase complex identify novel antiretroviral compounds. ACS Chem Biol (2009) 1.18
Diagnostic yield and clinical outcomes of capsule endoscopy. Gastrointest Endosc (2004) 1.17
Orphan nuclear receptor pregnane X receptor sensitizes oxidative stress responses in transgenic mice and cancerous cells. Mol Endocrinol (2005) 1.17
Association of genetic variants in the calcium-sensing receptor with risk of colorectal adenoma. Cancer Epidemiol Biomarkers Prev (2004) 1.16
Aberrant crypt foci: what we know and what we need to know. Clin Gastroenterol Hepatol (2007) 1.16
Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc (2002) 1.16
Rac1 leads to phosphorylation-dependent increase in stability of the p66shc adaptor protein: role in Rac1-induced oxidative stress. Mol Biol Cell (2005) 1.15
Variability in flexible sigmoidoscopy performance among examiners in a screening trial. Clin Gastroenterol Hepatol (2005) 1.13
Noninvasive testing for colorectal cancer: a review. Am J Gastroenterol (2005) 1.13
Fluorous mixture synthesis of (-)-dictyostatin and three stereoisomers. Org Lett (2006) 1.12
Down-regulating cold shock protein genes impairs cancer cell survival and enhances chemosensitivity. J Cell Biochem (2009) 1.12
Using the transtheoretical model to stage screening behavior for colorectal cancer. Health Educ Behav (2003) 1.11
Identification of ATP citrate lyase as a positive regulator of glycolytic function in glioblastomas. Int J Cancer (2010) 1.11
Theory and applications of surface plasmon resonance, resonant mirror, resonant waveguide grating, and dual polarization interferometry biosensors. Sensors (Basel) (2010) 1.09
Pyrimidinone-peptoid hybrid molecules with distinct effects on molecular chaperone function and cell proliferation. Bioorg Med Chem (2007) 1.09
A multicenter study of prevalence and risk factors for aberrant crypt foci. Clin Gastroenterol Hepatol (2009) 1.08
Identification of nuclear matrix protein alterations associated with human colon cancer. Cancer Res (2002) 1.08
Retracted Highly specific urine-based marker of bladder cancer. Urology (2005) 1.07
Select pyrimidinones inhibit the propagation of the malarial parasite, Plasmodium falciparum. Bioorg Med Chem (2009) 1.07
Development of automated imaging and analysis for zebrafish chemical screens. J Vis Exp (2010) 1.07
Total synthesis and biological evaluation of C16 analogs of (-)-dictyostatin. J Med Chem (2007) 1.06
Proteomic characterization of harvested pseudopodia with differential gel electrophoresis and specific antibodies. Lab Invest (2005) 1.06
Retracted Functional characterization of the bladder cancer marker, BLCA-4. Clin Cancer Res (2004) 1.06
Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Cancer Res (2005) 1.06
A majority of the cancer/testis antigens are intrinsically disordered proteins. J Cell Biochem (2011) 1.05
The Group 3 LIM domain protein paxillin potentiates androgen receptor transactivation in prostate cancer cell lines. Cancer Res (2003) 1.04
Redox regulation of Cdc25B by cell-active quinolinediones. Mol Pharmacol (2005) 1.04
Total synthesis and biological evaluation of pederin, psymberin, and highly potent analogs. J Am Chem Soc (2011) 1.04
Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia. Prostate (2010) 1.03
Retracted Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers. Cancer Res (2007) 1.03
Tubulin assembly, taxoid site binding, and cellular effects of the microtubule-stabilizing agent dictyostatin. Biochemistry (2005) 1.03
Streamlined syntheses of (-)-dictyostatin, 16-desmethyl-25,26-dihydrodictyostatin, and 6-epi-16-desmethyl-25,26-dihydrodictyostatin. J Am Chem Soc (2010) 1.02
Likelihood of missed and recurrent adenomas in the proximal versus the distal colon. Gastrointest Endosc (2011) 1.02
Cancer/testis antigens and urological malignancies. Nat Rev Urol (2012) 1.01
Genotoxicity assessed by the comet and GPA assays following in vitro exposure of human lymphoblastoid cells (H9) or perinatal exposure of mother-child pairs to AZT or AZT-3TC. Environ Mol Mutagen (2007) 1.01
Azide-tetrazole equilibrium of C-6 azidopurine nucleosides and their ligation reactions with alkynes. J Org Chem (2010) 1.01
Increased expression of CYR61, an extracellular matrix signaling protein, in human benign prostatic hyperplasia and its regulation by lysophosphatidic acid. Endocrinology (2004) 1.00
The management of small polyps found by virtual colonoscopy: results of a decision analysis. Clin Gastroenterol Hepatol (2007) 0.99
The potential role of purine-rich element binding protein (PUR) alpha as a novel treatment target for hormone-refractory prostate cancer. Prostate (2008) 0.99
Identification of calreticulin as a nuclear matrix protein associated with human colon cancer. J Cell Biochem (2003) 0.99
Use of the novel marker BLCA-1 for the detection of bladder cancer. J Urol (2005) 0.98
Structure-activity and high-content imaging analyses of novel tubulysins. Chem Biol Drug Des (2007) 0.98
Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells. Oncogene (2003) 0.98
Nuclear structure as a source of cancer specific biomarkers. J Cell Biochem (2008) 0.97